EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)

Michael K Wong iD, Mohammed M Milhem iD, Joseph J Sacco iD, Judith Michels iD, Gino K In, Eva Muñoz Couselo iD, Dirk Schadendorf iD, Georgia M Beasley iD, Jiaxin Niu iD, Bartosz Chmielowski iD, Trisha M Wise-Draper iD, Tawnya Lynn Bowles iD und 17 weitere

Journal of Clinical Oncology · 20.11.2025 · 43 (33) · 3589-3599

DOI: 10.1200/jco-25-01346 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2025. Verfasst von Michael K Wong und 28 weiteren Autor:innen. Beteiligte Einrichtung: Roswell Park Comprehensive Cancer Center, Buffalo, NY. Hauptthemen laut MEDLINE: Nivolumab, Melanoma, Herpesvirus 1, Human, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Effective treatment options for melanoma after immune checkpoint blockade failure are limited. RP1 (vusolimogene oderparepvec) is a herpes simplex virus type 1–based oncolytic immunotherapy, here evaluated in combination with nivolumab in anti–PD-1–failed melanoma. METHODS Patients had advanced melanoma that had confirmed progression on anti–PD-1 (≥8 weeks, last prior treatment). RP1 was administered intratumorally (≤8 doses, ≤10 mL/dose; additional doses allowed) with nivolumab (≤2 years). The objective response rate (ORR) was assessed by independent central review using Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS Of 140 patients enrolled, 48.6% had stage IVM1b/c/d disease, 65.7% had primary anti–PD-1 resistance, 56.4% were PD-L1 negative, and 46.4% received prior anti–PD-1 and anti–cytotoxic T-lymphocyte antigen-4 therapy (43.6% in combination and 2.9% sequentially). Confirmed ORR (95% CI) was 32.9% (95% CI, 25.2% to 41.3%; 15.0% complete response). Responses occurred with similar frequency, depth, duration, and kinetics for injected and noninjected, including visceral lesions. The median (95% CI) duration of response was 33.7 (95% CI, 14.1 to not reached) months. Overall survival rates (95% CI) at 1 and 2 years were 75.3% (95% CI, 66.9% to 81.9%) and 63.3% (95% CI, 53.6% to 71.5%), respectively. Biomarker analysis demonstrated broad immune activation associated with response, including increased CD8 + T-cell infiltration and PD-L1 expression. Treatment-related adverse event rates were 77.1% grade 1/2, 9.3% grade 3, 3.6% grade 4, and no grade 5 events. CONCLUSION RP1 combined with nivolumab provided deep and durable systemic responses in patients with anti–PD-1–failed melanoma, including those with poor prognostic factors. The safety profile was favorable, with mostly grade 1/2 adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabMelanomaHerpesvirus 1, HumanImmune Checkpoint InhibitorsOncolytic VirotherapySkin NeoplasmsHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overProgrammed Cell Death 1 Receptor

Substanzen

NivolumabImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA.
  • The Clatterbridge Cancer Centre, Wirral, United Kingdom.
  • University of Liverpool, Liverpool, United Kingdom.
  • Département de Médecine Oncologique, Gustave Roussy, Villejuif, France.
  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.

ORCID-Profile: Michael K Wong, Mohammed M Milhem, Joseph J Sacco, Judith Michels, Eva Muñoz Couselo, Dirk Schadendorf, Georgia M Beasley, Jiaxin Niu, Bartosz Chmielowski, Trisha M Wise-Draper, Tawnya Lynn Bowles, Katy K Tsai, Céleste Lebbé, Mark R Middleton, Jason A Chesney, Ari M VanderWalde, Yousef Zakharia, Kevin J Harrington, Praveen K Bommareddy, Caroline Robert

Zitieren

APA

Wong, M. K., Milhem, M. M., Sacco, J. J., Michels, J., In, G. K., Muñoz Couselo, E., Schadendorf, D., Beasley, G. M., Niu, J., Chmielowski, B., Wise-Draper, T. M., Bowles, T. L., Tsai, K. K., Lebbé, C., Gaudy-Marqueste, C., Middleton, M. R., Skolariki, A., Samson, A., Chesney, J. A., …, & Robert, C. (2025). RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE). Journal of Clinical Oncology, 43(33), 3589-3599. https://doi.org/10.1200/jco-25-01346

Vancouver

Wong MK, Milhem MM, Sacco JJ, Michels J, In GK, Muñoz Couselo E, et al. RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE). Journal of Clinical Oncology. 2025;43(33):3589-3599. doi:10.1200/jco-25-01346

BibTeX
@article{Wong2025,
  author = {Wong, Michael K and Milhem, Mohammed M and Sacco, Joseph J and Michels, Judith and In, Gino K and Muñoz Couselo, Eva and Schadendorf, Dirk and Beasley, Georgia M and Niu, Jiaxin and Chmielowski, Bartosz and Wise-Draper, Trisha M and Bowles, Tawnya Lynn and Tsai, Katy K and Lebbé, Céleste and Gaudy-Marqueste, Caroline and Middleton, Mark R and Skolariki, Aglaia and Samson, Adel and Chesney, Jason A and VanderWalde, Ari M and Zakharia, Yousef and Harrington, Kevin J and Appleton, Elizabeth and Bommareddy, Praveen K and Zhu, Junhong and Viana, Marcus and Hou, Jeannie W and Coffin, Robert S and Robert, Caroline},
  title = {RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {33},
  pages = {3589--3599},
  doi = {10.1200/jco-25-01346}
}
Kostenlos starten →